August 2019 in “Key engineering materials” A microemulsion with Carthamus tinctorius extract effectively inhibits 5α-reductase and improves skin and hair follicle delivery.
May 2019 in “Australasian Journal of Dermatology” The conclusion is that managing hair loss conditions like FFA and melanoma requires individualized approaches, considering new findings and balancing treatment benefits with potential risks.
January 2019 in “Nihon Yakuri Gakkai nenkai yoshishu” Current treatments for lower urinary tract symptoms include α1-blockers, 5ARIs, PDE5 inhibitors, anticholinergic agents, and β3-adrenergic receptor agonists.
Antimalarial agents are effective for LPP, and intralesional steroids are effective for FFA.
February 2018 in “InTech eBooks” Diagnosing and treating PCOS is complex due to differing criteria and requires a team approach.
Different scalp and hair disorders are more common in certain ethnic groups, with the most common being androgenetic alopecia, which is treated with medications like minoxidil and finasteride.
Certain medications can negatively impact male fertility.
May 2017 in “Psychiatric news” BPH medications may increase the risk of self-harm and depression, especially in the first 18 months.
April 2017 in “The journal of sexual medicine” 5-alpha-reductase inhibitors significantly affect the penile tissue of hypertensive rats.
April 2017 in “The Journal of urology/The journal of urology” SHH protein helps nerve regeneration in hypertensive rats.
April 2017 in “The Journal of urology/The journal of urology” Long-term use of certain prostate drugs can worsen erectile dysfunction by changing penile tissue, especially in rats with high blood pressure.
March 2017 in “Journal of endourology” The journal retracted an article due to inaccurate statistics and asked the authors to revise and resubmit it.
February 2017 in “The Journal of urology/The journal of urology” Castration significantly reduces prostate size and BPH symptoms.
January 2017 in “Clinical approaches and procedures in cosmetic dermatology” Men are increasingly seeking quick-result cosmetic treatments for their thicker, oilier skin and hair loss issues.
August 2016 in “Journal of Investigative Dermatology” Some men don't respond to common hair loss treatments, but a new inhibitor, FOL-005, shows promise for targeting unwanted hair growth.
The article concludes that understanding the causes of hair loss and using continuous treatments like minoxidil and finasteride can help manage it, despite potential side effects.
The document explains how certain drugs block hormones to treat cancers like breast and prostate cancer.
Hormonal treatments can help with hair loss, acne, and excess hair growth, but it takes 3-6 months to see results and patients should know the possible side effects.
August 2012 in “Pharmaceutical Medicine” The document concludes that various medications and treatments can have significant, sometimes adverse, effects on health outcomes.
July 2012 in “The Journal of Urology” Testosterone increases muscle mass regardless of DHT conversion blocking.
The document concludes that hair loss in women can be treated with topical treatments or hormone therapy depending on the cause.
August 2010 in “The Journal of urology/The journal of urology” Male pattern baldness may be linked to prostate cancer risk.
Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.
July 2002 in “Journal of cosmetic dermatology” Hair loss can be treated with medications like finasteride and surgical methods like hair transplants.
June 2018 in “Actas Dermo-Sifiliográficas” New treatments improve hair loss solutions for different age groups and genders.
Treatments for hair loss vary, but cell-based options may be the future.
April 2015 in “The Journal of Urology” Finasteride reduces PSA levels by around 40-50% in BPH patients.
January 2023 in “Dermatologic Therapy” Intralesional corticosteroids and 5-alpha-reductase inhibitors are the best treatments for frontal fibrosing alopecia.
December 2022 in “International Journal of Molecular Sciences” Afatinib, neratinib, and zanubrutinib could be effective against KRASG12C-mutant tumors.
December 2022 in “JAMA network open” 5α-Reductase inhibitors may increase depression risk but not dementia or suicide.